AmbioPharm
North Augusta, SC, USA (+ Wuhan, China)
Program data pending ClinicalTrials.gov matching
—
Not Assessed
○ FDA Inspections
○ Clinical Trials
○ SEC Filings
✓ Press (8)
Signal Score & Pillar Breakdown
Quality Compliance
—
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs
— no verified data
Sponsors— no verified data
ModalitiesPeptide API (SPPS/LPPS/Hybrid), GLP-1 class peptides, Complex modified peptides
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability
—
Insufficient financial data. Score requires company profile or SEC filings.
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity
—
Insufficient capacity data. Score requires company profile with manufacturing site information.
Recent Press8 articles
Manufacturing site information being gathered
Modalities: Peptide API (SPPS/LPPS/Hybrid), GLP-1 class peptides, Complex modified peptides
Capacity assessment: 55.0/100
Recent News 8 articles
Amytrx Therapeutics Partners with CDMO AmbioPharm - Contract Pharma
AmbioPharm Provides an Update on South Carolina Headquarters Expansion - BioSpace
AmbioPharm To Utilize YMC Twin-Column Chromatography in Large Scale Peptide Production - Business Wire
AmbioPharm, a Global Peptide CDMO - Business Wire
AmbioPharm Provides an Update on Shanghai Campus Expansion and Resumption of Customer Visits - Business Wire
AmbioPharm Supports ONL Therapeutics with Peptide Manufacturing to Prepare for IND Application for Phase 2 Study - Business Wire
Local biopharmaceutical manufacturer welcomes new CEO to expanded facilities - The Augusta Chronicle
AmbioPharm Breaks Ground on $28M Expansion of Pharmaceutical Manufacturing Site in Shanghai - PharmiWeb.com
Represent this organization? Contact us to verify or update this profile.